China Blood Products Industry Report, 2011-2012
  • Jun/2012
  • Hard Copy
  • USD $2,400
  • Pages:112
  • Single User License
    (PDF Unprintable)       
  • USD $2,300
  • Code: ZYM029
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,600
  • Hard Copy + Single User License
  • USD $2,600
      
Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma volume and further intensified the tight supply of raw material plasma. But when it comes to the lot release volume, the blood product output in China grew as high as 15.4% YoY in 2011, and the market size rose 22% YoY to around RMB11.6 billion. Additionally, in consideration of 12th Five-Year Plan for Doubling Blood Product Supply proposed by the Minister of the Ministry of Health at the end of 2011, the issuance of Notice of the Ministry of Health on Management of Plasma Collection Stations in early 2012, and the domestic market demand & supply, the blood product market size in China is expected to maintain a high growth rate of over 20% in the five years to come.

However, the low degree of industry concentration, the companies’ weak R&D capabilities, short supply of raw material plasma and low plasma utilization rate affect the development of Chinese blood product industry to some extent. The blood products released in overseas market divide into around 40 varieties, and the international blood product giants can extract about 15 varieties of blood products from plasma, while among Chinese companies, Beijing Tiantan Biological Products Co., Ltd. can produce at most 11 varieties from plasma. Moreover, Chinese blood product market is principally concentrated on human albumin and human immunoglobulin (pH4) for intravenous injection which pose low requirements on technologies. In 2011, the lot release volume of the two products made up 53.4% and 16.8% of the total release volume respectively.

Product Structure of Blood Products in China (by Lot Release Volume), 2009-2011
20120617.gif

Blood coagulation factor and thrombin products feature the largest demand gap in China, but there are less domestic supply and fewer producers. In 2011, the manufacturers of Human Coagulation Factor VIII in China just include Shanghai RAAS Blood Products, Green Cross China and Hualan Biological Engineering Inc., with lot release volume adding up to 350,000 bottles, and the producers of Human Prothrombin Complex are Hualan Biological Engineering Inc., Shanghai RAAS Blood Products and Shanghai Xinxing Medicine, with lot release volume totaling 200,000 bottles. Essentially, subsidiaries under China National Biotech Group and other Groups that possess production capacity and obtain governmental approvals in Coagulation Factor VIII and IX do not conduct production in recent years. With the intensifying contradiction between supply and demand, the government may launch intervention measures to enable the enterprises with the approval to restart the manufacturing of these products to raise overall supply of products of this sort.

Although taking such factors like home market demand into account, China has allowed the import of some blood products, but the imports are confined to human albumin and recombinant coagulation factor. Moreover, blood product manufacturing is a sector with no allowance for foreign capital. The imported human albumin almost makes up 50% market share, and the proportion reached 43.3% in 2011.

Following the tougher conflict between supply & demand and the loosening of policies in China, foreign brands quicken their pace of tapping into Chinese market. In May 2012, SFDA approved the release of Baxter’s ADVATE (Recombinant Human Coagulation Factor VIII for injection) in China which was another foreign brand of coagulation factor after the imported Bayer’s Recombinant Coagulation Factor VIII in 2007. Moreover, Pfizer is applying for quick approval program for its Recombinant Coagulation Factor IX (obtained from Wyeth).

The report resolves around the followings:

20120114.gifThe plasma volume, distribution of plasma stations, market size and supply & demand of Chinese blood product industry;
20120114.gifCompetition pattern, policy climate and import & export of Chinese blood product industry;
20120114.gifMarket supply & demand and competitive landscape of 8 blood products such as human albumin, human immunoglobulin (pH4) for intravenous injection and coagulation factor, etc.
20120114.gifStatus quo, operation, plasma collection station and product lot release volume of 9 Chinese blood product manufacturers.

1. Profile of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Overview of China Blood Products Industry
2.1 Market Size
2.2 Development Status
2.3 Market Supply & Demand
2.3.1 Supply 
2.3.2 Demand 
2.4 Market Competition
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policies
2.5.3 Domestic Biopharmaceutical Market
2.6 Import & Export

3. Blood Product Market Segments in China
3.1 Human Albumin
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1Supply & Demand
3.2.2 Competition Pattern
3.3 Coagulation Factor
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.8 Rabies Immunoglobulin
3.8.1 Supply & Demand
3.8.2 Competition Pattern

4. Key Manufacturers in China
4.1 Hualan Biological Engineering Inc.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Clients and Suppliers
4.1.6 R&D and Investment
4.1.7 Blood Products
4.2 Shanghai RAAS Blood Products Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Clients and Suppliers
4.2.6 R&D and Investment
4.3 Beijing Tiantan Biological Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 Blood Products
4.4 China Biologic Products Inc.
4.4.1 Profile
4.4.2 Operation
4.4.4 Cost Analysis
4.4.5 Clients and Suppliers
4.4.6 Shandong Taibang Biological Products Co., Ltd.
4.4.7 Guiyang Qianfeng Biological Products Co., Ltd.
4.4.8 Xi’an Hui Tian Blood Products Co., Ltd.
4.5 Jiangxi Boya Biopharmaceutical Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Clients and Suppliers
4.5.6 Output & Sales Volume and Price
4.5.7 R&D and Investment
4.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Blood Products
4.7 CNBG Shanghai Institute of Biological Products
4.7.1 Profile
4.7.2 Blood Products
4.8 Shanxi Kangbao Biological Product Co., Ltd.
4.8.1 Profile
4.8.2 Blood Products
4.9 Green Cross
4.9.1 Profile
4.9.2 Blood Products
Basic Components of Blood
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Categories and Comparison of Recombinant Blood Products in China and Worldwide
Blood Product Industry Chain
Blood Product Market Scale in China, 2003-2015E
Lot Release Volume of Blood Products (by Product) in China, 2007-2011
Product Structure of Blood Products in China (by Lot Release Volume), 2009-2011 
Annual Plasma Volume in China, 2002-2011 
Geographical Distribution of Plasma Collection Station Resources in China, by the End of 2011
Medical Insurance Coverage in Mainstream Blood Products in China
Comparison of Per Capita Usage of Blood Products between China and Developed Countries
Distribution of Plasma Collection Stations, Plasma Volume and Blood Products Revenue of Chinese Major Blood Product Manufacturers, 2011
Comparison among Blood Product Manufacturing Enterprises in China by Product Line
Blood Products in Overseas Countries
On-going Clinical Trial of New Indications Overseas
Global Blood Products Manufacturers
Major Policies Concerning Blood Products in China
Sales Value and Total Profit of Biological & Biochemical Product Industry in China, 2008-2011
Ratio of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2010
Market Share of Major Manufacturers of Human Albumin in China (by Lot Release Volume), 2007-2011
Comparison between China and USA by Consumption of Human Immunoglobulin (pH4) for Intravenous Injection, 2010
Lot Release Volume and Its Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2010 
Prices of Human Immunoglobulin (pH4) for Intravenous Injection in China and Other Countries
Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2011
Lot Release Volume and Its Growth Rate of Coagulation Factor VIII in China, 2008-2011 
Market Share of Major Manufacturers of Coagulation Factor VIII in China (by Lot Release Volume), 2008-2011
Comparison between Human-derived Coagulation Factor VIII and Recombinant Coagulation Factor VIII
Lot Release Volume and Its Growth Rate of Hepatitis B Immunoglobulin in China, 2008-2011 
Market Share of Major Manufacturers of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Human Immunoglobulin in China, 2008-2011 
Market Share of Major Manufacturers of Human Immunoglobulin in China (by Lot Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Human Prothrombin Complex in China, 2008-2011
Market Share of Manufacturers of Human Prothrombin Complex in China (by Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Tetanus Immunoglobulin in China, 2008-2011 
Market Share of Major Manufacturers of Tetanus Immunoglobulin in China (by Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Human Rabies Immunoglobulin in China, 2008-2011 
Market Share of Major Manufacturers of Human Rabies Immunoglobulin in China (by Release Volume), 2008-2011
Revenue and Total Profit of Hualan Biological, 2007-2012
Revenue Breakdown of Hualan Biological by Industry, 2007-2011 
Revenue Structure of Hualan Biological by Industry, 2007-2011
Revenue Breakdown of Hualan Biological by Product, 2007-2011 
Revenue Structure of Hualan Biological by Product, 2007-2011
Revenue Breakdown of Hualan Biological by Region, 2007-2011 
Revenue Structure of Hualan Biological by Region, 2007-2011
Gross Margin of Hualan Biological by Industry, 2007-2011
Gross Margin of Hualan Biological by Product, 2007-2011
Hualan Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
Hualan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement,2007-2011
R&D Costs and % of Total Revenue of Hualan Biological, 2007-2011
Distribution of Plasma Collection Stations of Hualan Biological, 2011
Lot Release Volume of Blood Products of Hualan Biological, 2008-2011 
Proportion of Blood Products Release Volume of Hualan Biological, 2008-2011
Revenue and Gross Margin of Blood Products of Hualan Biological, 2007-2011 
Revenue and Gross Margin of Blood Products of Hualan Biological (by Product), 2007-2011
Distribution of Plasma Collection Stations of Shanghai RAAS Blood Products Co., Ltd, by the End of 2011
Revenue and Profit of Shanghai RAAS, 2007-2012
Lot Release Volume of Blood Products of Shanghai RAAS Blood Products Co., Ltd, 2007-2011
Proportion of Blood Products Release Volume of Shanghai RAAS, 2007-2011
Revenue Breakdown of Shanghai RAAS by Product, 2007-2011 
Revenue Structure of Shanghai RAAS by Product, 2007-2011
Revenue Breakdown of Shanghai RAAS by Region, 2007-2011
Revenue Structure of Shanghai RAAS by Region, 2007-2011
Gross Margin of Shanghai RAAS by Product, 2007-2011
Shanghai RAAS’s Revenue from Top 5 Clients and % of Total Revenue,2007-2011
Name List and Revenue Contribution of Shanghai RAAS’s Top 5 Clients, 2011
Shanghai RAAS’s Procurement from Top 5 Suppliers and % of Total Procurement,2007-2011
R&D Costs and % of Total Revenue of Shanghai RAAS,2007-2011
Revenue and Net Income of Tiantan Biological’s Major Joint-stock Companies, 2011
Revenue and Total Profit of Beijing Tiantan Biological, 2007-2012
Revenue Breakdown of Beijing Tiantan Biological by Industry, 2007-2011
Revenue Breakdown of Beijing Tiantan Biological by Region, 2007-2011
Gross Margin of Beijing Tiantan Biological by Industry, 2007-2011
Beijing Tiantan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 
2007-2011
Beijing Tiantan Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
Name List and Revenue Contribution of Top 5 Clients of Beijing Tiantan Biological’s Top 5 Clients, 2011
Distribution of Plasma Collection Stations of Beijing Tiantan Biological, by the End of 2011
Revenue and Gross Margin of Blood Products of Beijing Tiantan Biological, 2007-2011
Lot Release Volume of Blood Products of Chengdu Rongsheng, 2007-2011
Equity Structure of China Biologic Product Inc.
Revenue and Operating Income of China Biologic Products Inc., 2007-2011
Revenue Structure of China Biologic Products Inc. by Product, 2008-2011
Plasma Collection Costs of China Biologic Products Inc., 2008-2011
China Biologic Products Inc.’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2011
Name List and Revenue Contribution of China Biologic Products Inc.’s Top 5 Clients, 2011
Name List and Procurement Contribution of China Biologic Products Inc.’s Top 10 Suppliers, 2011
Lot Release Volume of Blood Products of Shandong Taibang, 2007-2011
Lot Release Volume of Blood Products of Guiyang Qianfeng, 2007-2011 
Lot Release Volume of Blood Products of Xi’an Hui Tian, 2007-2011
Plasma Inventory, Plasma Collection Amount and Plasma Volume of Boya Biopharmaceutical, 2009-2011
Distribution and Collection Amount of Plasma Collection Stations of Boya Biopharmaceutical, 2009-2011
Revenue and Profit of Boya Biopharmaceutical, 2009-2012
Revenue Breakdown of Boya Biopharmaceutical by Product, 2009-2011
Revenue Structure of Boya Biopharmaceutical by Product, 2009-2011
Lot Release Volume of Blood Products of Boya Biopharmaceutical, 2007-2011
Revenue Breakdown of Boya Biopharmaceutical by Region, 2009-2011
Revenue Structure of Boya Biopharmaceutical by Region, 2009-2011
Gross Margin of Boya Biopharmaceutical by Product, 2009-2011
Boya Biopharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2011 
Name List and Revenue Contribution of Boya Biopharmaceutical’s Top 5 Clients, 2011
Boya Biopharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement,2009-2011 
Name List and Procurement Contribution of Boya Biopharmaceutical’s Top 5 Suppliers, 2011
Output & Sales Volume and Inventory of Boya Biopharmaceutical by Product, 2009-2011 
Prices of Boya Biopharmaceutical by Product, 2009-2011
R&D Costs and % of Total Revenue of Boya Biopharmaceutical, 2009-2011
Blood Product R&D Projects and Progress of Boya Biopharmaceutical, by the End of 2011
Distribution of Plasma Collection Stations of Yuanda Shuyang, by the End of 2011
Lot Release Volume of Blood Products of Yuanda Shuyang, 2007-2011
Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2007-2011
Distribution of Plasma Collection Stations of CNBG Shanghai Institute of Biological Products, by the End of 2011
Distribution of Plasma Collection Stations of Shanxi Kangbao, by the End of 2011
Lot Release Volume of Blood Products of Shanxi Kangbao, 2007-2011 
Distribution of Plasma Collection Stations of Green Cross, by the End of 2011
Lot Release Volume of Blood Products of Green Cross, 2007-2011 

China Human Vaccine Industry Report, 2011-2012

After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release ...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统